ALZAMEND NEURO INC (ALZN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.66-2.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Alzamend Neuro is developing new drugs for Alzheimer's disease. It has a strong patent portfolio and a unique drug platform. Recent analyst EPS estimates have improved from -0.98 to -0.67 next quarter. The company is advancing clinical trials and aims to meet big unmet medical needs.
The company is loss-making and faces Nasdaq delisting risk. It has no revenue and negative EPS of -2.6 expected this year. Recent equity sales dilute shareholders. The biotech sector is risky and the stock is under selling pressure.
The market prices in continued losses and no revenue growth. Analyst EPS estimates remain negative but have slightly improved. There is no clear consensus on future revenue or valuation. Our view is cautious given the lack of positive earnings or sales.
Breaks if: additional large equity issuances or delisting occurs
Breaks if: failure to achieve key clinical milestones or trial setbacks
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is characterized as a speculative growth opportunity. The current thesis state indicates a watchful approach due to recent volatility and ongoing financial struggles.
The market seems to have priced in a high level of risk, as ALZN is currently loss-making and has a weak earnings quality. There is an expectation that the Healthcare sector's overall momentum may support ALZN, but this is contingent on the performance of key sector players.
Fundamentals are likely to remain weak in the near term, with increasing operating losses and cash burn. Management's focus on capital raising is evident, but compliance issues and financial performance suggest limited progress.
The future of ALZN hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX. If these companies continue to perform well, it may provide some support, but any negative shifts could further impact ALZN's situation.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: mean EPS fails to improve or worsens beyond -0.7 next quarter
In the next 1 to 3 years, ALZN's outlook remains uncertain, driven by high risks and weak fundamentals. Not investment advice.